<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-6-12876A0101-AFR-12250</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) 2019-2023</narrative>
   <narrative xml:lang="SV">Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) 2019-2023</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">African Academy of Sciences (AAS) har hos Sida ans&#xF6;kt om 32,2 miljoner SEK f&#xF6;r att administrera finansiering av och tillhandah&#xE5;lla kapacitetsst&#xE4;rkande och n&#xE4;tverksbildande aktiviteter f&#xF6;r afrikanska forskare som beviljats anslag fr&#xE5;n Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) under perioden 2019-11-01 till 2023-12-31. Av ovann&#xE4;mnda beloppet kommer 18,1 miljoner SEK att vidarebefordras till sju afrikanska forskare som deltar i fem transnationella forskningskonsortier som har ans&#xF6;kt om Sida-finansiering och valdes ut i JPIAMR 2019 utlysningen &quot;Diagnostics and Surveillance of Antimicobial Resistance: Development of tools, technologies and methods for global use&quot;.

M&#xE5;ls&#xE4;ttningen med partnerskapet mellan Sida, AAS och JPIAMR &#xE4;r att flera l&#xE4;nders resurser, infrastruktur och styrkor sluts samman f&#xF6;r att facilitera innovativa forskningsprojekt f&#xF6;r att bromsa utveckling och spridning av AMR med en s.k. One Health-ansats som intergerar human, djur och milj&#xF6;h&#xE4;lsa; att st&#xF6;dja och &#xF6;ka deltagandet av forskare i l&#xE5;ginkomstl&#xE4;nder i Afrika s&#xF6;der om Sahara och andra l&#xE4;nder i omr&#xE5;det d&#xE4;r Sverige har bilateralt utvecklingssamarbete i den globala kampen mot AMR; och att bygga kapacitet och st&#xF6;dja bildandet av ett n&#xE4;tverk av AMR-forskare p&#xE5; den afrikanska kontinenten.

JPIAMR &#xE4;r en global organisation och samarbetsplattform d&#xE4;r 27 nationer arbetar tillsammans f&#xF6;r att begr&#xE4;nsa utvecklingen och konsekvenserna av AMR med hj&#xE4;lp av en One Health-ansats. I JPIAMR utlysningen 2019, d&#xE4;r 19 forskningsfinansi&#xE4;rer fr&#xE5;n 15 l&#xE4;nder ing&#xE4;r, finansieras 12 transnationella forskningsprojekt med totalt 12,1 miljoner Euro (cirka 129,7 miljoner SEK). Sidas bidrag p&#xE5; 1,71 miljoner euro (cirka 18,1 miljoner SEK) motsvarar ca. 14% av den totala finansieringen.</narrative>
   <narrative xml:lang="EN">The African Academy of Sciences (AAS) has applied to Sida for funding of 32.2 million SEK to provide grant management services plus additional capacity building and networking activties for African grantees funded by research calls of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) during the period 2019-11-01 until 2023-12-31. Of the 32.2 million SEK, 18.8 million SEK will be forwarded to seven African researchers participating in five transnational research consortia that have applied for Sida funding and were selected in the JPIAMR 2019 call &quot;Diagnostics and Surveillance of Antimicobial Resistance: Development of tools, technologies and methods for global use&quot;.

The objectives of the proposed Sida partnership with the JPIAMR and AAS is to combine resources, infrastructures, and strengths of multiple countries in order to facilitate innovative research projects to curb AMR with an One Health approach integrating human, animal and evironmental health; to support and increase the participation of researchers in low-income countries in sub-Saharan Africa and other sub-Saharan countries where Sweden has bilateral development cooperation in the global fight against AMR; and to build capacity and support the formation of a network of AMR researchers on the African continent.

JPIAMR is a global collaborative organization and platform, engaging 27 nations to curb AMR with a One Health approach. In the JPIAMR 2019 call, 19 funding organizations from 15 countries went together to fund transnational research projects. Funding was allocated to 12 projects with a total sum of 12.1 million Euro (approx. 129.7 million SEK) with Sida&apos;s contribution of 1.71 millio Euro (approx. 18.1 million SEK) representing ca. 14% of the total funding.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The objetives of the intervention are:
to combine resources, infrastructures, and strengths of multiple countries in order to facilitate innovative research projects to curb AMR with a One Health approach;
to support and increase the participation of researchers in low-income countries in sub-Saharan Africa and other sub-Saharan countries where Sweden has bilateral development cooperation in the global fight against AMR;
to build capacity and support the formation of a network of AMR researchers on the African continent.</narrative>
  </description>
  <participating-org ref="23000" role="2">
   <narrative xml:lang="EN">AAS/African Academy of Sciences</narrative>
  </participating-org>
  <participating-org ref="23000" role="4" type="23">
   <narrative xml:lang="EN">AAS/African Academy of Sciences</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-6" role="3" type="10">
   <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2019-11-01" type="1"></activity-date>
  <activity-date iso-date="2019-11-01" type="2"></activity-date>
  <activity-date iso-date="2024-06-30" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
   </organisation>
   <telephone>+46 8 698 50 00</telephone>
   <email>sida@sida.se</email>
   <website>www.sida.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Valhallav&#xE4;gen 199, 105 25 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="298" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Africa, regional</narrative>
  </recipient-region>
  <sector code="122" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Basic Health</narrative>
  </sector>
  <sector code="12250" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Infectious disease control</narrative>
  </sector>
  <tag code="3.3" vocabulary="3">
   <narrative xml:lang="EN">3.3 - By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.</narrative>
   <narrative xml:lang="SV">3.3 - Senast 2030 utrota epidemierna av aids, tuberkulos, malaria och f&#xF6;rsummade tropiska sjukdomar samt bek&#xE4;mpa hepatit, vattenburna sjukdomar och andra smittsamma sjukdomar.</narrative>
  </tag>
  <tag code="3.9" vocabulary="3">
   <narrative xml:lang="EN">3.9 - By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contamination.</narrative>
   <narrative xml:lang="SV">3.9 - Till 2030 v&#xE4;sentligt minska antalet d&#xF6;ds- och sjukdomsfall till f&#xF6;ljd av skadliga kemikalier samt f&#xF6;roreningar och kontaminering av luft, vatten och mark.</narrative>
  </tag>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <tag code="3.D" vocabulary="3">
   <narrative xml:lang="EN">3.d - Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.</narrative>
   <narrative xml:lang="SV">3.d - St&#xE4;rka alla l&#xE4;nders, i synnerhet utvecklingsl&#xE4;ndernas, kapacitet n&#xE4;r det g&#xE4;ller tidig varning, riskreducering och hantering av nationella och globala h&#xE4;lsorisker.</narrative>
  </tag>
  <tag code="6.3" vocabulary="3">
   <narrative xml:lang="EN">6.3 - By 2030, improve water quality by reducing pollution, eliminating dumping and minimizing release of hazardous chemicals and materials, halving the proportion of untreated wastewater and substantially increasing recycling and safe reuse globally.</narrative>
   <narrative xml:lang="SV">6.3 - Till 2030 f&#xF6;rb&#xE4;ttra vattenkvaliteten genom att minska f&#xF6;roreningar, stoppa dumpning och minimera utsl&#xE4;pp av farliga kemikalier och material, halvera andelen obehandlat avloppsvatten och v&#xE4;sentligt &#xF6;ka &#xE5;tervinningen och en s&#xE4;ker &#xE5;teranv&#xE4;ndning globalt.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">892932.772131685</value>
  </budget>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">0</value>
  </budget>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">207148.7367230584</value>
  </budget>
  <budget>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">0</value>
  </budget>
  <budget>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">0</value>
  </budget>
  <planned-disbursement>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">892932.772131685</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">-5e-10</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">180654.6654385616</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2022-01-01"></period-start>
   <period-end iso-date="2022-12-28"></period-end>
   <value currency="USD" value-date="2022-01-01">1e-10</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2023-01-01"></period-start>
   <period-end iso-date="2023-12-28"></period-end>
   <value currency="USD" value-date="2023-01-01">0</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-11-01"></transaction-date>
   <value currency="USD" value-date="2019-11-01">1080825.41059</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-28"></transaction-date>
   <value currency="USD" value-date="2019-12-28">892932.772131685</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-06-28"></transaction-date>
   <value currency="USD" value-date="2021-06-28">207148.7367230584</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-10-28"></transaction-date>
   <value currency="USD" value-date="2021-10-28">-26494.088773333</value>
  </transaction>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/12876_039190-19GrantAgreementbetweenSidaandAfricanAcademyofSciencesregardingJPIAMRca2589377_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Avtal insats Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)</narrative>
   </title>
   <category code="A09"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/12876_037373-19Beslutominsats,_JointProgrammingInitativeonAntimicrobialResistance(JPIA2581436_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om insats Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://documents.iati.openaid.se/document/forsk/12876_020646-21Decisiononterminationofagreement(12876)Jointprogramminginitiativeonant2942819_1_1.pdf">
   <title>
    <narrative xml:lang="SV">Beslut om upps&#xE4;gning av avtal JPIAMR/AAS</narrative>
   </title>
   <category code="A11"></category>
  </document-link>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Results achieved</narrative>
    <narrative xml:lang="SV">Uppn&#xE5;dda resultat</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Sida engaged in the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) Call on Diagnostics and Surveillance 2019 to support participation of African researchers and research institutions in transnational&#xA0;research projects. Projects were selected in a highly competitive&#xA0;two-step proposal and review process, and among the granted projects were five with participants from institutions in seven African countries (Burkina Faso, Gambia, Kenya, Madagascar, Tanzania, Togo and Uganda) that had requested funding from Sida.
Through partnership with Sida, the Grand Challenges Africa team at the Alliance for Accelerating Excellence in Science in Africa (AESA)&#xA0;at the African Academy of Sciences (AAS) supports grant management for Africa-based JPIAMR&#xA0;partners and provides&#xA0;capacity building activities&#xA0;and support for the formation of a network of AMR researchers on the African continent.
In 2020, the AAS finalized the due diligence review for the African partners involved in the transnational&#xA0;research&#xA0;consortia selected in the 2019 JPIAMR&#xA0;call.&#xA0;The due diligence included self-assessments according to the Good Financial Grant Practice (GFGP) standard,&#xA0;desk reviews of GFGP&#xA0;documents and budget reviews. It was planned to perform due diligence site visits to five of the seven grantees,&#xA0;but&#xA0;due to the COVID-19 pandemic and related travel restrictions, only one site visit could be performed. Following&#xA0;satisfactory completion of due diligence reviews, the AAS issued award letters and terms and conditions for the grant to all grantees; projects&#xA0;started during quarters 2 and 3 in 2020. The first set of project reports is due in June 2021.
Due to COVID-19 related restrictions, it was not possible to hold an inception meeting gathering all grantees. However, all JPIAMR&#xA0;grantees were invited to participate in the virtual Grand Challenges Annual Meeting in October 2020 for capacity building and networking.</narrative>
   </description>
   <indicator ascending="0" measure="5">
    <title>
     <narrative xml:lang="EN">Not applicable</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">No indicator available - only a description of the activity results is published</narrative>
    </description>
   </indicator>
  </result>
  <sida:contribution contributionid="12876" xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
  <sida:strategies xmlns:sida="http://sida.se/ns/strategies#">
   <sida:strategy code="1140102" currency="SEK" strategy-amount="0" strategy-end-date="2022-12-31" strategy-start-date="2015-01-01">
    <sida:title>Research cooperation 2015-2022</sida:title>
    <sida:titleSV>Forskningssamarbete 2015-2022</sida:titleSV>
   </sida:strategy>
  </sida:strategies>
 </iati-activity>
</iati-activities>
